Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study

BACKGROUND & AIM: In randomised clinical trials, the type II anti-CD20 antibody obinutuzumab has been shown to be more effective than rituximab for therapy of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). However, this enhanced efficacy was linked with elevated rates of high-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirich, Theo, Zwickl-Traxler, Elisabeth, Pecherstorfer, Martin, Singer, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057460/
https://www.ncbi.nlm.nih.gov/pubmed/30042825
http://dx.doi.org/10.18632/oncotarget.25714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057460/
https://www.ncbi.nlm.nih.gov/pubmed/30042825
http://dx.doi.org/10.18632/oncotarget.25714

Ejemplares similares